Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: Buddy Smellgood who wrote (24424)	6/16/2005 3:10:45 PM
From: Bucky Katt	Respond to of 48461

Very interesting. Rat NFLD has been working on this for a long time... I think we were pretty hot on it in the $4-$5 range PolyHeme® is a unique human hemoglobin-based oxygen-carrying blood substitute in development for the treatment of urgent, large volume blood loss in trauma and surgical settings, with a particular focus on settings where blood is not immediately available. PolyHeme® is a solution of chemically modified human hemoglobin which simultaneously restores lost blood volume and hemoglobin levels and can be rapidly and massively infused. PolyHeme® has been rapidly and safely infused in clinical trials in sufficiently massive quantities to be useful in the treatment of large volume blood loss. PolyHeme’s unique characteristics make it the ideal resuscitative fluid: * Simultaneously restores lost blood volume and hemoglobin levels * Is universally compatible * Is immediately available * Supports life without red blood cells * Reduces risk of viral disease * Does not cause transfusion reactions * Allows rapid, massive infusion * Has extended shelf life of over 12 months * Has been well tolerated in clinical trials to date * Is manufactured from human blood northfieldlabs.com